{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T01:32:50Z","timestamp":1768527170397,"version":"3.49.0"},"reference-count":47,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2016.00122","type":"journal-article","created":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T09:13:26Z","timestamp":1463562806000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction"],"prefix":"10.3389","volume":"6","author":[{"given":"Michael C.","family":"Repka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Guleria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn A.","family":"Cyr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Yung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harsha","family":"Koneru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard N.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyuan","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian T.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranay","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simeng","family":"Suy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anatoly","family":"Dritschilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean P.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2016,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3389\/fonc.2014.00290","article-title":"Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancer","volume":"4","author":"Rana","year":"2014","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/1748-717X-9-163","article-title":"Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer","volume":"9","author":"Arscott","year":"2014","journal-title":"Radiat Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3389\/fonc.2015.00151","article-title":"Dysuria following stereotactic body radiation therapy for prostate cancer","volume":"5","author":"Janowski","year":"2015","journal-title":"Front Oncol"},{"issue":"12","key":"B4","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors","volume":"358","author":"Sanda","year":"2008","journal-title":"N Engl J Med"},{"issue":"21","key":"B5","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1200\/JCO.2003.01.199","article-title":"Time course and predictors of symptoms after primary prostate cancer therapy","volume":"21","author":"Talcott","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"B6","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ijrobp.2013.08.019","article-title":"Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials","volume":"87","author":"King","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"B7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.radonc.2015.07.048","article-title":"Multi-variable models predicting specific patient-reported acute urinary symptoms after radiotherapy for prostate cancer: results of a cohort study","volume":"116","author":"Cozzarini","year":"2015","journal-title":"Radiother Oncol"},{"issue":"4","key":"B8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/pcan.2010.33","article-title":"From bad to worse: comorbidity severity and quality of life after treatment for early-stage prostate cancer","volume":"13","author":"Daskivich","year":"2010","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"B9","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S0360-3016(01)02657-8","article-title":"Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: a prospective study","volume":"52","author":"Locke","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"B10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0360-3016(01)02658-X","article-title":"Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation","volume":"52","author":"Crook","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"B11","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.ijrobp.2004.01.017","article-title":"Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy","volume":"59","author":"Hinerman-Mulroy","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"B12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.ijrobp.2004.12.068","article-title":"Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity","volume":"62","author":"Allen","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"B13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ijrobp.2013.10.042","article-title":"Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer","volume":"88","author":"Ghadjar","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"B14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ijrobp.2014.06.031","article-title":"Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints for treatment planning","volume":"90","author":"Hathout","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"B15","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.ijrobp.2008.05.059","article-title":"Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial","volume":"73","author":"King","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"B16","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0360-3016(99)00246-1","article-title":"Tamsulosin palliates radiation-induced urethritis in patients with prostate cancer: results of a pilot study","volume":"45","author":"Prosnitz","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"B17","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0090-4295(02)01840-X","article-title":"Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy","volume":"60","author":"Merrick","year":"2002","journal-title":"Urology"},{"issue":"1","key":"B18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijrobp.2004.09.036","article-title":"Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study","volume":"62","author":"Elshaikh","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"B19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.radonc.2015.07.016","article-title":"Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy","volume":"116","author":"Evans","year":"2015","journal-title":"Radiother Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1748-717X-8-58","article-title":"Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience","volume":"8","author":"Chen","year":"2013","journal-title":"Radiat Oncol"},{"issue":"3","key":"B21","doi-asserted-by":"publisher","first-page":"E249","DOI":"10.1016\/j.ijrobp.2015.07.1174","article-title":"Quality of life outcomes for low- and intermediate-risk prostate cancer patients treated with 5-fraction stereotactic body radiation therapy","volume":"93","author":"Kaplan","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3389\/fonc.2014.00122","article-title":"Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer","volume":"4","author":"Woo","year":"2014","journal-title":"Front Oncol"},{"issue":"5","key":"B23","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.1016\/j.prro.2015.02.001","article-title":"Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer","volume":"5","author":"Seymour","year":"2015","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"B24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.prro.2015.01.006","article-title":"Dosimetric parameters predict short-term quality-of-life outcomes for patients receiving stereotactic body radiation therapy for prostate cancer","volume":"5","author":"Gomez","year":"2015","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"B25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3109\/0284186X.2015.1037011","article-title":"Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer","volume":"55","author":"Kole","year":"2016","journal-title":"Acta Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1748-717X-7-82","article-title":"Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy","volume":"7","author":"Vainshtein","year":"2012","journal-title":"Radiat Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1748-717X-9-118","article-title":"Early results of urethral dose reduction and small safety margin in intensity-modulated radiation therapy (IMRT) for localized prostate cancer using a real-time tumor-tracking radiotherapy (RTRT) system","volume":"9","author":"Shimizu","year":"2014","journal-title":"Radiat Oncol"},{"issue":"1","key":"B28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.radonc.2009.11.003","article-title":"I-125 seed planning: an alternative method of urethra definition","volume":"94","author":"Anderson","year":"2010","journal-title":"Radiother Oncol"},{"issue":"2","key":"B29","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0360-3016(03)00583-2","article-title":"Dosimetric consequences of using a surrogate urethra to estimate urethral dose after brachytherapy for prostate cancer","volume":"57","author":"Lee","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"B30","doi-asserted-by":"publisher","first-page":"e775","DOI":"10.1016\/j.ejrad.2013.09.011","article-title":"MRI findings of radiation-induced changes in the urethra and periurethral tissues after treatment for prostate cancer","volume":"82","author":"Marigliano","year":"2013","journal-title":"Eur J Radiol"},{"issue":"6","key":"B31","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.brachy.2014.03.002","article-title":"High-dose-rate brachytherapy as monotherapy for prostate cancer","volume":"13","author":"Demanes","year":"2014","journal-title":"Brachytherapy"},{"key":"B32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3389\/fonc.2011.00048","article-title":"Six-dimensional correction of intra-fractional prostate motion with CyberKnife stereotactic body radiation therapy","volume":"1","author":"Lei","year":"2011","journal-title":"Front Oncol"},{"issue":"1","key":"B33","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ijrobp.2008.04.051","article-title":"Intrafractional motion of the prostate during hypofractionated radiotherapy","volume":"72","author":"Xie","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"B34","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3109\/0284186X.2012.760848","article-title":"Health-related quality of life in prostate cancer","volume":"52","author":"Torvinen","year":"2013","journal-title":"Acta Oncol"},{"issue":"5","key":"B35","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"issue":"6","key":"B36","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0090-4295(00)00858-X","article-title":"Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","volume":"56","author":"Wei","year":"2000","journal-title":"Urology"},{"issue":"5","key":"B37","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/00005650-200305000-00007","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"issue":"2","key":"B38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.clon.2003.11.006","article-title":"Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study","volume":"16","author":"Henderson","year":"2004","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"3","key":"B39","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.ijrobp.2005.03.046","article-title":"Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry","volume":"63","author":"Van Gellekom","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"B40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.radonc.2004.07.026","article-title":"Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy","volume":"73","author":"Williams","year":"2004","journal-title":"Radiother Oncol"},{"issue":"3","key":"B41","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.1016\/j.ijrobp.2015.07.477","article-title":"Stereotactic body radiation therapy for intermediate-risk prostate cancer: five-year outcomes from a multi-institutional study","volume":"93","author":"Meier","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"B42","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.clon.2014.08.007","article-title":"Prostate stereotactic body radiotherapy \u2013 first UK experience","volume":"26","author":"Tree","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13014-015-0488-3","article-title":"Sexual, irritative, and voiding outcomes, following stereotactic body radiation therapy for prostate cancer","volume":"10","author":"Rana","year":"2015","journal-title":"Radiat Oncol"},{"issue":"3","key":"B44","doi-asserted-by":"publisher","first-page":"E197","DOI":"10.1016\/j.ijrobp.2015.07.1050","article-title":"Hypofractionated stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: a multi-institutional phase 2 analysis","volume":"93","author":"Gill","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15","key":"B45","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1002\/cncr.26699","article-title":"Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial","volume":"118","author":"McBride","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"B46","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1016\/j.ijrobp.2011.04.026","article-title":"Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial","volume":"81","author":"Tsumura","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"B47","doi-asserted-by":"publisher","first-page":"S198","DOI":"10.1016\/j.ijrobp.2015.07.473","article-title":"PATRIOT trial: randomized phase 2 study of prostate stereotactic body radiation therapy comparing 11 versus 29 days overall treatment time","volume":"93","author":"Quon","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Frontiers in Oncology"],"original-title":[],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T20:03:13Z","timestamp":1567886593000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/Article\/10.3389\/fonc.2016.00122\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,18]]},"references-count":47,"URL":"https:\/\/doi.org\/10.3389\/fonc.2016.00122","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,18]]}}}